No Data
Express News | HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Express News | Cantor Fitzgerald Reiterates Overweight on PDS Biotechnology
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets
Buy Rating Affirmed on PDS Biotechnology's Promising HNSCC Treatment Developments
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets
PDS Biotechnology Announces Details of Virtual KOL Event
PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets